Diagnosing cardiac disease during pregnancy: imaging modalities

Ntobeko AB Ntusi, Petronella Samuels, Sulaiman Moosa, Ana O Mocumbi

Abstract
Pregnant women with known or suspected cardiovascular disease (CVD) often require cardiovascular imaging during pregnancy. The accepted maximum limit of ionising radiation exposure to the foetus during pregnancy is a cumulative dose of 5 rad. Concerns related to imaging modalities that involve ionising radiation include teratogenesis, mutagenesis and childhood malignancy. Importantly, no single imaging study approaches this cautionary dose of 5 rad (50 mSv or 50 mGy). Diagnostic imaging procedures that may be used in pregnancy include chest radiography, fluoroscopy, echocardiography, invasive angiography, cardiovascular computed tomography, computed tomographic pulmonary angiography, cardiovascular magnetic resonance (CMR) and nuclear techniques.

Echocardiography and CMR appear to be completely safe in pregnancy and are not associated with any adverse foetal effects, provided there are no general contra-indications to MR imaging. Concerns related to safety of imaging tests must be balanced against the importance of accurate diagnosis and thorough assessment of the pathological condition. Decisions about imaging in pregnancy are premised on understanding the physiology of pregnancy, understanding basic concepts of ionising radiation, the clinical manifestations of existent CVD in pregnancy and features of new CVD. The cardiologist/physician must understand the indications for and limitations of, and the potential harmful effects of each test during pregnancy. Current evidence suggests that a single cardiovascular radiological study during pregnancy is safe and should be undertaken at all times when clinically justified. In this article, the different imaging modalities are reviewed in terms of how they work, how safe they are and what their clinical utility in pregnancy is. Furthermore, the safety of contrast agents in pregnancy is also reviewed.

Keywords: medical imaging, pregnancy, cardiovascular disease, X-ray, echocardiography, computed tomography, cardiovascular magnetic resonance, nuclear cardiology

Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
Ntobeko AB Ntusi, FCP (SA), DPhil, ntobeko.ntusi@gmail.com

Cape University Body Imaging Centre, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Petronella Samuels, BTech Rad

Military Hospital, Wynberg, Cape Town, South Africa
Sulaiman Moosa, FFRad Diag (SA)

Instituto Nacional de Saúde and Department of Medicine, University Eduardo Mondlane, Maputo, Mozambique
Ana O Mocumbi, MD, PhD, FESC

Submitted 3/9/15, accepted 4/3/16
Cardiovasc J Afr 2016; 27: 95–103 www.cvja.co.za

DOI: 10.5830/CVJA-2016-022

Pregnant women with known cardiovascular disease (CVD) or a newly diagnosed cardiac condition in pregnancy often require cardiovascular imaging during the pregnancy to confirm the diagnosis, to assess disease severity and stratify risk, to prognosticate, to plan for appropriate management and to assess response to therapy (Table 1). A variety of cardiovascular imaging modalities are available for such purposes and include X-ray [which encompasses chest radiography, cardiovascular computed tomography (CCT), computed tomographic pulmonary angiography (CTPA), coronary computed tomographic angiography (CCTA), fluoroscopy and invasive angiography], echocardiography, cardiovascular magnetic resonance (CMR) and nuclear techniques.

Of these, diagnostic X-ray and nuclear procedures emerge as the greatest source of concern for patients and clinicians alike. However, most diagnostic radiological procedures do not expose the pregnant woman to a degree of radiation that would threaten the well-being of the developing pre-embryo, embryo or foetus. Furthermore, as cardiological imaging focuses mainly on the chest, there is minimal direct exposure of the lower abdomen, where the baby may lie within the main X-ray beam; hence radiation doses to the developing foetus tend to be small. The mechanisms of action, safety and clinical utility of various cardiovascular imaging modalities in pregnancy are considered below.

We performed a systematic search of the published literature on cardiovascular imaging in pregnancy, published in the English language, through PUBMED (January 1966 to December 2015), OVID, Cochrane Database of Systematic Reviews and hand search of reference lists from selected articles. All search engines were searched using the key words: ‘pregnancy’, ‘cardiovascular imaging’, ‘echocardiography’, ‘X-ray’, ‘angiography’, ‘fluoroscopy’, ‘computed tomography’, ‘cardiovascular magnetic resonance’ and ‘nuclear cardiology’. Articles with important insights about cardiovascular imaging in pregnancy are included.

Ionising radiation and pregnancy
Ionising radiation refers to electromagnetic radiation produced by X-ray equipment, the radioactive isotopes (radionuclides) used for radiation therapy (Table 2). The accepted cumulative dose of ionising radiation during pregnancy is 5 rad (which is also equal to 50 mSv or 50 mGy), and no single diagnostic study exceeds this maximum. For example, the amount of exposure to the foetus from a two-view chest X-ray of the mother is only 0.00007 rad.
Termination of pregnancy on the grounds of ionising radiation exposure is not recommended unless there is sufficient documentation that the estimated foetal dose exceeds 15 rad (150 mSv). An important determinant of the consequence of radiation exposure in pregnancy is the stage in which the radiation exposure occurs. In the first two weeks following conception or the second two weeks from the last menstrual period, the developing embryo is resistant to the malforming effects of X-rays. However, the developing embryo is sensitive to the lethal effects of X-rays, although doses much higher than 5 rad (50 mSv) are necessary to cause a miscarriage. From the third to the eighth week of pregnancy, in the period of early embryonic development, the embryo is hardly affected, in terms of birth defects, pregnancy loss, or growth retardation, unless the exposure is substantially above 200 mSv. From the eighth to the 15th week of pregnancy, the embryo or foetus is sensitive to the effects of radiation, particularly on the central nervous system (CNS). However, for the development of microcephaly and other CNS malformations, the radiation exposure has to be sufficiently high. The threshold for an observed effect on intelligence quotient is estimated to be greater than 30 rad (300 mSv).

Cardiovascular diagnostic studies do not reach these levels and, therefore, these effects are rarely of concern for patients. The most sensitive period for CNS teratogenesis is between eight and 15 weeks of gestation, therefore non-urgent radiological testing should be avoided during this time. Rare consequences of prenatal radiation exposure include a slight increase in the incidence of childhood leukaemia and, possibly, a small change in the frequency of genetic mutations. Such exposure is not an indication for pregnancy termination, however.

Appropriate counselling of patients before radiological studies is performed is critical. After 20 weeks of gestation, the foetus is fully developed and it again becomes resistant to the effects of radiation exposure. At this late stage, there is no evidence of increased risk of birth defects or miscarriage from radiological diagnostic studies.

**Table 1. Rationale for use and indications for imaging of CVD in pregnancy**

| Evaluation of biventricular structure, size and function | Conventional units |
|---------------------------------------------------------|--------------------|
| Evaluation of native and prosthetic valve disease | SI units |
| Evaluation of pregnancy-induced hypertension and hypertensive heart failure of pregnancy | 1 rem = 1 rad for X-rays |
| Evaluation of congenital heart disease | 1 Sv = 100 rem |
| Evaluation of myocarditis | (1 rem = 1 rad for X-rays) |
| Evaluation of specific cardiomyopathies | 1 Sv = 100 rem |
| • Dilated cardiomyopathy | | |
| • Peripartum cardiomyopathy | | |
| • Hypertrophic cardiomyopathy | | |
| • Arrhythmogenic right ventricular cardiomyopathy | | |
| • Iron-overload cardiomyopathy | | |
| • Restrictive cardiomyopathy | | |
| • Myocardial infiltration (e.g. sarcoidosis) | | |
| • Left ventricular non-compaction | | |
| • Systemic rheumatoid diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis) | | |
| • Other less-common diseases (e.g. Chagas disease, Churg-Strauss syndrome) | | |
| Evaluation of pericardial disease | | |
| • Pericarditis | | |
| • Pericardial effusions | | |
| • Pericardial tumours | | |
| • Pericardial effusive-constrictive syndrome | | |
| • Pericardial constriction | | |
| Evaluation of great vessels and pulmonary veins | | |
| Evaluation of cardiac masses (differentiation of tumour from thrombus) | | |
| Evaluation of infective endocarditis | | |
| Evaluation of ischaemic heart disease | | |
| • Diagnosis of myocardial infarction and its sequelae | | |
| • Assessment of myocardial viability | | |
| • Assessment for inducible ischaemia | | |
| • Coronary imaging | | |
| • Assessment of suspected coronary artery fistula | | |
| • Assessment of suspected anomalous coronary origins | | |
| Differentiation of ischaemic versus non-ischaemic cardiomyopathy | | |
| Evaluation of mechanical dysynchrony | | |
| Evaluation of unexplained heart failure or stroke | | |

Possible deleterious effects of ionising radiation include (1) genetic consequences, the risks of which can be assessed only from animal studies; (2) carcinogenesis, which can be assessed from survivors of nuclear bombings and patients exposed for medical reasons; and (3) teratogenic effects on the developing embryo or foetus. Most cardiovascular diagnostic procedures expose the embryo and foetus to less than 50 mSv, which does not increase reproductive risks (either birth defects or miscarriage).

The reported dose of radiation with consequent increased incidence of birth defects or miscarriage is above 200 mSv.
Radiation-induced malignancy

Exposure to as little as 1 or 2 rad has been associated with an increase in childhood malignancies, especially leukaemia, occurring in a stochastic fashion. For example, the background rate of leukaemia in children is about 3.6 per 10 000. Exposure to 1 or 2 rad increases this rate to five per 10 000. While these doses do fall within the range of some radiographic studies, the absolute increase of risk (≈ 1 in 10 000) is very small. Therefore, physicians should carefully weigh the risks and benefits of any radiographic study and include the mother in the decision-making process whenever possible.

Radiation-induced mutagenesis

Radiation can cause germ-line mutations, potentially affecting future generations. Although radiation is commonly believed to create bizarre new mutations, data show that it usually merely increases the frequency of mutations occurring naturally in the general population. The dosage required to double this baseline mutation rate is between 50 and 100 rad, far more than the radiation doses occurring in common cardiovascular radiographic studies.

The most important factor for physicians to remember is that the currently accepted maximum limit of ionising radiation exposure to the foetus during pregnancy is a cumulative dose of 5 rad (50 mSv or 50 mGy).

Non-ionising radiation and pregnancy

The reproductive risk of non-ionising radiation, which includes electromagnetic fields from computers, microwave ovens, microwave communication systems, cellular phones, power lines, household appliances, heating pads and warming blankets, airport metal screening devices and diagnostic ultrasound has been studied extensively. Two national committees of scientists in the US evaluated the risk from these non-ionising radiation sources. The first report was published in 1993 from the Oak Ridge Associated University panel created by the White House, while the second was the product of the committee of the National Academy of Sciences. Both of these groups concluded that the reproductive risk of non-ionising radiation is minimal, if even existent.

Chest radiography

The chest X-ray is the most commonly performed diagnostic cardiovascular radiographic examination, and is able to produce accurate images of the heart, lungs, airways, blood vessels and the bones of the spine and chest. The chest X-ray utilises small amounts of radiation (0.00002 to 0.00007 rad) when a focused beam of radiation is passed through the body, resulting in a black-and-white image recorded on special film or a computer.

X-rays are able to differentiate tissues in the body because of varying densities (each tissue allows a different amount of radiation to pass through and expose the X-ray-sensitive film). Dense bone absorbs much of the radiation while soft tissue, such as heart muscle, allows more of the X-rays to pass through. Consequently bones appear white on the X-ray, soft tissue shows up in shades of grey and air appears black.

Medical indications for chest X-ray include heart failure, pulmonary embolism, pneumonia, pneumoconiosis, posteriorly displaced heart, and following percutaneous coronary intervention (PCI).

Fluoroscopy and invasive angiography

Fluoroscopy is a type of medical imaging that shows a continuous X-ray image on a monitor, much like an X-ray movie. Fluoroscopy is routinely used to screen suspected stuck prosthetic valves and for percutaneous transvenous mitral commissurotomy (PTMC) in those with symptomatic mitral stenosis in pregnancy. Furthermore, fluoroscopy is the basis for imaging during invasive angiographic procedures (including coronary angiography and haemodynamic studies). There are many situations where the benefit of performing these procedures is much greater than any small possible harm that might arise from radiation exposure.

For a typical fluoroscopic study, the amount of radiation occurring is in the range of 0.001 to 0.05 rad; dosage depends on duration of fluoroscopic time.

As always with any medical exposure, each particular procedure must be clinically justified, including taking into account when the procedure needs to occur and the anticipated radiation dose to the foetus. Once justified, due diligence is taken to optimise when and how the procedure is performed to minimise radiation exposure to the foetus, consistent with achieving the desired clinical outcome. The radiation exposure to the foetus predominantly arises from scattered radiation within the patient.

Some of the main methods for minimising the dose to the foetus include: (1) restricting the X-ray beam size to as small as is necessary; (2) choosing the direction of the primary beam so that it is as far away from the foetus as possible; (3) ensuring that the overall exposure time is as short as possible; (4) selecting appropriate exposure factors; (5) calculating the dose by a knowledgeable medical physicist, if there is concern; and (6) using a lead apron on the table to shield any primary beam from the X-ray tube reaching the foetus (Table 3).
Echocardiography

Echocardiography is an imaging modality that uses high-frequency (2–10 MHz) sound waves to image cardiac structures and to give reproducible information about cardiac structure and function. Ultrasound is produced when a piezo-electric crystal, mounted in a transducer, is stimulated by an electric current.30

Ultrasound waves are not audible and are harmless to tissue at the intensities used in diagnostic imaging. The passage of sound waves depends on the acoustic impedance of tissues. Most ultrasound waves pass through tissues to deeper structures further from the surface, but reflected sound returns to strike the crystal, deforming it and producing electric signals, which correspond to the degree of deformation.31 This electrical information is transformed so it can be displayed on a cathode-ray tube as pulses of light. Due to the speed of sound within the body being relatively constant, the depth of the tissue interface can be calculated, and reflected echoes are displayed on the screen on a depth scale.32

Blood reflects little sound and appears relatively black/hypoechoic compared with the myocardium, which reflects more of the ultrasound and appears relatively white/hyperchoic. The heart valves are even more echogenic. Neither bone nor air is a good transmission medium for ultrasound waves; therefore as the heart is surrounded by lung and the bony cage of the thoracic cavity, the ultrasound beam must be aimed through parasternal, thoracic cavity, the ultrasound beam must be aimed through as the heart is surrounded by lung and the bony cage of the thoracic cavity, the ultrasound beam must be aimed through

Selecting appropriate exposure factors
Defer abdominal examinations if possible; imaging examinations of the thorax are associated with negligible risks to the conceptus
Whenever possible, ultrasound is the preferred modality for abdominal imaging in pregnancy
Magnetic resonance imaging is emerging as an alternative in centres where it is widely available
Using a lead apron on the table to shield any primary beam from the X-ray tube reaching the foetus
Calculations of dose by a knowledgeable medical physicist if there is concern
The radiation dose should be kept as low as reasonably achievable (ALARA principle)

Table 3. Approaches to minimising foetal radiation during cardiovascular imaging in pregnancy

| Approach                                      |
|-----------------------------------------------|
| Restricting the X-ray beam size to as small as is necessary |
| Choosing the direction of the primary beam so that it is as far away from the foetus as possible |
| Ensuring that the overall exposure time is as short as possible |
| Selecting appropriate exposure factors         |

Cardiovascular computed tomography (CCT)

Computed tomography (CT) is a diagnostic imaging procedure that uses X-rays to demonstrate cross-sectional images of the body acquired in different orthogonal planes. The cross-sections or slices are reconstructed from the measurements of attenuation coefficients of X-ray beams in the volume of the object studied.33 The fundamental principle of CT is premised on tissue density traversed by the X-ray beam, which can be calculated from the attenuation coefficient. In other words, CT permits reconstruction of tissue density by 2D sections perpendicular to the axis of the acquisition system. Unlike X-ray radiography, the detectors of the CT scanner do not produce an image, but rather measure the transmission of a thin beam (1–10 mm) of X-rays through a full scan of the body, and the image of that section is taken from different angles, allowing retrieval of information on the depth of the tissues imaged.40

Complex mathematical algorithms are used to construct an image from the raw data; a typical CT image is composed of 512 rows, each of 512 pixels, i.e. a square matrix of 512 × 512 = 262 144 pixels (one for each voxel). A typical CCT study gives 0.06 to 0.09 rad.41 Similarly, the effective radiation dose for CT pulmonary angiogram (CTPA) protocols is generally between 2.2 and 7 mSv (0.02–0.07 rad).42

Often, for CCT and CTPA, the imaging field of view includes the lungs and breasts; the radiation dose can be reduced by...
shielding, lowering the peak kilovoltage or lowering the tube current.43 In general, lower-dose protocols result in images with poor resolution and greater noise, therefore reductions must consider image quality and diagnostic confidence.44

CTPA remains the imaging modality of choice for diagnosis of pulmonary embolism in pregnancy and is preferred for its general superiority over ventilation-perfusion scintigraphy.45 Ventilation-perfusion scintigraphy may be indeterminate in up to 25% of patients imaged in pregnancy.46 In addition, the foetal radiation dose from CTPA is substantially less than that from ventilation-perfusion scintigraphy in all trimesters, even if half-dose perfusion-only scintigraphy is used.47,48

Cardiovascular magnetic resonance

CMR is a remarkably powerful imaging modality, free of ionising radiation, with high spatial and temporal resolution, performed via excitation of hydrogen protons within a powerful magnetic field.49 The strong magnetic field aligns the nuclear magnetisation spin of the hydrogen protons, which are then excited by radiofrequency (RF) pulses (pulse sequences). After the RF pulses are switched off, the protons give off energy as they precess back to their equilibrium magnetisation; this dissipated energy is detected by the MR receiver coils. Fourier transformation is then used to convert frequencies into images.

The signal from a given tissue (e.g. heart muscle) is determined by the proton density (PD) and by two specific relaxation parameters: longitudinal relaxation time (T1) and transverse relaxation time (T2).49 PD, T1 and T2 vary substantially for different tissues, and may vary substantially within the same tissue from health to disease; these differences are used to generate contrast in MR images.50 To prevent artifacts from cardiac motion, CMR images are generated with fast sequences gated to the R wave of the electrocardiogram. Respiratory motion may be eliminated by acquiring CMR images in end-expiratory breath-hold.

MR has been used to evaluate obstetric, placental and foetal abnormalities in pregnant patients for more than 25 years. MR imaging is recognised as a beneficial diagnostic tool and is utilised routinely to assess multiple conditions that affect the pregnant patient (Fig. 3) as well as the foetus. To date, there has been a paucity of systematic studies directed towards determining the relative safety of using MR procedures in pregnant patients.51 There has been no evidence of harm from the use of CMR and other forms of MR imaging in pregnancy.51

Safety concerns include possible bio-effects of the static magnetic field of the MR system, risks associated with exposure to the gradient magnetic fields, the potential adverse effects of RF energy, possible adverse effects related to heating and to the combination of these three electromagnetic fields, possible acoustic injury from the vibration and noise in the scanner, and possible toxicity from gadolinium-based contrast agents used in patients with renal dysfunction.52 MR environment-related risks are difficult to assess for pregnant patients due to the number of possible permutations of the various factors that are present in this setting (e.g. differences in field strengths, pulse sequences, exposure times).

However, several experimental and clinical investigations of the effects of MR in pregnancy showed no evidence of injury or harm to the foetus or the mother.53,54 Even the few human studies performed in pregnant human subjects exposed to MR imaging or the MR environment have not reported adverse outcomes for the subjects.55,56 In recent times, there has been increasing concern that acoustic noise associated with MR may impact on the foetus; however this remains unproven in recent large studies.57

In summary, CMR up to 3T appears to be safe in all stages of pregnancy.58 Higher field strengths have not been evaluated in the setting of pregnancy. CMR, where available, together with echocardiography, remains preferable to any studies using ionising radiation for cardiovascular imaging in pregnancy, in particular during the first trimester. Despite the lack of harm

Fig. 3. CMR imaging in a pregnant woman with Marfan syndrome with previous spinal surgery and a prosthetic mitral valve (for severe mitral regurgitation). (A) anterior–posterior projection of chest radiograph showing scoliosis, spinal rods and prosthetic mitral valve. (B) CMR showing coronal oblique view of the left ventricular outflow with a dilated aortic root (max. 49 mm at the sinuses), effacement of the sinotubular junction and a dilated proximal ascending aorta. (C) A right ventricular (RV) transverse stack showing a normal RV and right atrium, with a normal LV size, sigmoid septum and artifact from the mitral valve prosthesis and minimal artifact from the spinal rods. (D) MRI of thoracic spine showing an incidental finding of a thoracic cord syrinx.
from MR in pregnancy, the current guidelines of the FDA require labelling of MR devices to indicate that the safety of MRI with regard to the foetus ‘has not been established’.

Nuclear cardiovascular imaging

Diagnostic nuclear medicine investigations also involve ionising radiation. Unlike X-rays, nuclear techniques involve the inhalation, ingestion or injection of a small quantity of a radioactive isotope bound in a substance that targets a particular organ, for example the heart. The gamma radiation emitted by the radioactive isotope is detected outside the body by electronic receptors of a gamma camera, which displays images or functional data about the heart.62

The most commonly used radioisotope, technetium-99m (\(^{99m}\)Tc), is a metastable daughter product following negative beta decay of molybdenum-99. \(^{99m}\)Tc decays to \(^{99}\)Tc with a half-life of six hours, releasing a mono-energetic gamma photon of 140 keV.60

Nuclear studies that may be performed during pregnancy include ventilation-perfusion scintigraphy for diagnosis of pulmonary embolism, myocardial perfusion imaging where \(^{99m}\)Tc may be combined with several compounds that localise to active myocardial cells, allowing ischaemic areas of the heart to be determined, and, less commonly, cardiac ventriculography where \(^{99m}\)Tc can be used to evaluate cardiac function (ejection fraction) by imaging the ventricles. The dose of radiation passed on to the foetus during a ventilation-perfusion scan is about 0.05 rad.60

Along with conventional gamma scintigraphic imaging, the two major nuclear imaging techniques are positron-emission tomography (PET) and single photon-emission computed tomography (SPECT). Both imaging modalities are now standard in the major nuclear medicine services.

PET is based on the principle of positron annihilation by using radionuclides that decay through positive beta decay.62 Positrons generated by the decay combine with an electron and annihilate, releasing two photons, with energies of 0.51 MeV, in the process. The photons are released in opposite directions.

The most commonly used compound for PET imaging is fluoro-2-deoxyglucose (\(^{18}\)FDG), which is initially metabolised within the cell, is unable to progress to the citric acid cycle, and is not easily excreted by the cell.62 Hence, cells that have a high glucose metabolism concentrate. \(^{18}\)FDG, can then be imaged. The sections are reconstructed by algorithms, similar to but more complex than those used for conventional CT, to accommodate the 3D acquisition geometries.60 Correction by considering the physical phenomena provides an image representative of the distribution of the tracer within the heart. In PET scanning, an effective dose of the order of 8 mSv is delivered to the patient.60

SPECT imaging is based on detectors that rotate around the patient to obtain a digital representation of a 3D radioactive distribution of the chest. The injected radioactive tracers emit during their disintegration, gamma photons, which are detected by an external detector after passing through the surrounding tissue.60 In SPECT, the main radioactive isotopes are \(^{99m}\)Tc, iodine and thallium-201 (which is used primarily for studies on the heart). To increase the sensitivity and resolution of SPECT systems, converging channel collimators were developed.60

Both PET and SPECT benefit from electrocardiographic gating used to enhance tomographic myocardial scintigraphy. Therefore, the radioactivity from the myocardium and the electrical activity of the heart are coupled. Depending on the procedure, the mother and baby will generally receive a small radiation dose with SPECT. It is unlikely that any diagnostic nuclear medicine investigation would result in the radiation dose of the foetus approaching 20 mGy. It is ideal that radioactive isotopes are avoided during pregnancy. However, if there is a real clinical need for such imaging to be performed, the risk to the mother and foetus is minimal.60

Contrast agents

A variety of oral and intravascular contrast agents are used with X-ray and MR procedures. Radiopaque agents used with CT and conventional radiography contain derivatives of iodine and have not been studied comprehensively in human pregnancy. However, iohexol, iopamidol, iothalamate, ioversol, ioxaglate and metrizamide have been studied in animals and do not appear to be teratogenic.61

Neonatal hypothyroidism has been associated with some iodinated agents taken during pregnancy.60 Therefore iodine-based contrast agents are relatively contra-indicated in pregnancy, unless absolutely essential for a correct diagnosis. Studies requiring views before and after the administration of contrast agents will necessarily have greater radiation exposure. While most contrast agents pass into the breast milk, they have not been associated with problems in nursing babies. Despite in vitro concerns, iodinated contrast agents seem safe to use in pregnancy.60 Radioactive isotopes of iodine are mutagenic and are absolutely contra-indicated during the pregnancy.60

Paramagnetic contrast agents used during CMR have not been studied systematically in pregnant women. Animal studies have demonstrated increased rates of spontaneous abortion, skeletal abnormalities, and visceral abnormalities when given at two to seven times the recommended human dose.60 It is not clear whether gadolinium-based contrast agents are excreted into human breast milk. It is important to emphasise that gadolinium-based contrast agents have not been associated with any harm in human pregnancy.60,61

The 2007 American College of Radiology (ACR) guidance for safe MR practices (expanded and updated in 2013) recommends that intravenous gadolinium should be avoided in pregnancy and should only be used if absolutely essential, until there is further information about these agents.60,61 Consequently, the FDA has classified gadolinium as a category C drug, meaning it can be considered in pregnancy ‘if the potential benefits justify the potential risks to the fetus’.

Safety counselling

When a pregnant mother considers any radiation exposure, the most prominent question in her mind is likely to be, ‘Is this safe for my baby?’ To answer this question, the physician must carefully choose words that will help a patient understand the real, although very small, risks of exposure. The general population’s total risk of spontaneous abortion, major malformations, mental retardation and childhood malignancy is approximately 286 per 1 000 deliveries. Exposing a foetus to 0.50 rad adds only about 0.17 cases per 1 000 deliveries to this baseline rate, or about one additional case in 6 000.60 Such numbers often do not make much
Table 4. Doses to the foetus from radiological and nuclear medicine examinations

| Examination                          | Estimated foetal dose (mGy) |
|--------------------------------------|-----------------------------|
| Chest radiograph                     | < 0.0001                    |
| Pulmonary CTA                        | 0.01–0.66                   |
| CCTA (prospective gating)            | 1.0                         |
| CCTA (retrospective gating)          | 3.0                         |
| Abdominopelvic CTA                   | 6.7–56.0                    |
| Direct fluoroscopy (groin to heart catheter passage) | 0.094–0.244 mGy/min         |
| Coronary angiography                 | 0.074                       |
| Electrophysiological procedures      | 0.0023–0.012 mGy/min        |
| Lung perfusion                       | 0.6                         |
| Lung ventilation                     | 0.005–0.09                  |
| Myocardial perfusion                 | 5.3–17                      |
| Gated blood pool                     | 6.0                         |
| PET viability                        | 6.3–8.1                     |
| PET perfusion                        | 2.0                         |
| Maximum recommended dose             | 5 rad or 50 mGy             |

sense to patients, and it is incumbent on the clinician to take the time to allay fears, ensuring good and clear communication during counselling.

“Safe” is a relative term but one that physicians should not be afraid to use. When a radiographic study is needed for appropriate management of a pregnant patient, the ACR recommends that “health care workers should tell patients that X-rays are safe and provide patients with a clear explanation of the benefits of X-ray examinations.”

One tool that physicians may consider using to reassure patients is Table 3, which compares the dosage of radiation provided by various common diagnostic studies with the accepted limit of 5 rad (50 mSv). A patient’s particular study could also be plotted on this graph, showing the clear margin of safety that exists for all single diagnostic studies.

Conclusion

Pregnant women with known or suspected CVD often require cardiovascular imaging. The accepted maximum limit of ionising radiation exposure to the foetus during pregnancy is a cumulative dose of 5 rad (50 mSv or 50 mGy). Concerns related to imaging modalities that involve ionising radiation include teratogenesis, mutagenesis and childhood malignancy. Importantly, no single imaging study approaches this cautious dose of 5 rad (Table 4). Elective studies may be deferred until the pregnancy is over or the gestational period is beyond 20 weeks, and there are several strategies that may be employed to minimise radiation to the foetus (Table 3). Echocardiography and CMR appear to be completely safe in pregnancy and are not associated with any adverse foetal effects, provided there are no general contraindications to MR imaging. Current evidence suggests that a single cardiovascular radiological study during pregnancy is safe and should be undertaken at all times when clinically justified.

As a general guide, centres where medical imaging is performed should have signs to remind mothers to notify the staff if they may be pregnant. The potential risks of each imaging modality should be discussed with the mother before she undergoes such imaging. Pregnant women must be made to understand that exposure from a single diagnostic procedure does not result in harmful foetal effects. Specifically, exposure to less than 5 rad has not been associated with an increase in foetal anomalies or pregnancy loss. Therefore concerns about possible effects of high-dose ionising radiation exposure should not prevent medically indicated diagnostic X-ray procedures from being performed on pregnant women. Consultation with an expert in dosimetry calculation may be helpful in calculating estimated foetal dose when multiple diagnostic X-ray procedures are performed in pregnancy.

In general, the radiation safety principle, ALARA (as low as reasonably achievable), minimising radiation and release of radioactive materials should be employed at all times. In addition, the use of iodine-based contrast agents for X-ray, fluoroscopy and CT scanning, and the use of gadolinium-based contrast agents for CMR are safe in pregnancy and should be used when the potential benefit justifies the potential risk to the foetus. However, the use of radioactive isotopes of iodine is contra-indicated for therapeutic use during pregnancy.

Dr Ntusi acknowledges support from the National Research Foundation and Medical Research Council of South Africa.

References

1. ACOG Committee on Obstetric Practice. ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol 2004; 104(3): 647–651.
2. Hall EJ. Scientific view of low-level radiation risks. Radiographics 1991; 11(3): 509–518.
3. Brent RL. Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposure. Teratology 1999; 59: 182–204.
4. International Commission on Radiological Protection. Pregnancy and medical radiation. Annals of the International Commission on Radiological Protection. Oxford: Pergamon Press, 2000, Publication 84.
5. Gray JE. Safety (risk) of diagnostic radiology exposures. In: American College of Radiology. Radiation Risk: a Primer. Reston (VA): ACR’ 1996: 15–17.
6. Brent RL. The effect of embryonic and fetal exposure to X-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. Semin Oncol 1989; 16: 347–68.
7. Parry RA, Glaze SA, Archer BR. The AAPM/RSNA physics tutorial for residents. Typical patient radiation doses in diagnostic radiology. Radiographics 1999; 19: 1289–1302.
8. Wieseler KM, Bhargava P, Kanal KM, Vaidya S, Stewart BK, Dighe MK. Imaging in pregnant patients: examination appropriateness. Radiographics 2010; 30(5): 1215–1233.
9. Streffer C, Shore R, Konermann G, et al. Biological effects after prenatal irradiation (embryo and fetus). A report of the International Commission on Radiological Protection. Ann Int Comm Radiol Protect 2003; 33(1–2): 5–206.
10. McCollough CH, Shueeler BA, Atwell TD, Braun NN, Renger DM, Brown DL, et al. Radiation exposure and pregnancy: should we be concerned? Radiographics 2007; 27: 909–918.
11. Toppenberg KS, Hill DA, Miller DP. Safety of radiographic imaging during pregnancy. Am Fam Physician 1999; 59(7): 1813–1818.
12. Logansky K. Do low doses of ionizing radiation affect the human brain? Data Science J 2009: 8: 13–35.
13. Wagner LK, Lester RG, Saldana LR. Exposure of the Pregnant Patient to Diagnostic Radiations: a Guide to Medical Management. Madison, USA: Medical Physics Publishing, 1997.
14. Williams PA, Fletcher S. Health effects of prenatal radiation exposure. *Am Fam Physician* 2010; 82(5): 488–493.
15. Blot WJ, Miller RW. Mental retardation following in utero exposure to the atomic bombs of Hiroshima and Nagasaki. *Radiology* 1973; 106: 617–619.
16. Yamazaki JN, Schull WJ. Perinatal loss and neurological abnormalities among children of the atomic bomb: Nagasaki and Hiroshima revisited, 1949 to 1989. *J Am Med Assoc* 1990; 264: 605–609.
17. Otake M, Schull WJ. In utero exposure to A-Bomb radiation and mental retardation: a reassessment. *Br J Radiol* 1984; 57: 409–414.
18. Miller RW. Epidemiological conclusions from radiation toxicity studies. In: Fry RJ, Grahn D, Griem ML, Rust JH, eds. *Late Effects of Radiation*. London: Taylor & Francis, 1970.
19. Bithell JF, Stiller CA. A new calculation of the carcinogenic risk of obstetric X-raying. *Stat Med* 1988; 7: 857–864.
20. Colletti PM, Lee KH, Elkayam U. Cardiovascular imaging of the pregnant patient. *Am J Roentgenol* 2013; 200: 515–521.
21. Schull WJ, Otake M. Cognitive function and prenatal exposure to ionizing radiation. *Teratology* 1990; 59: 222–226.
22. Committee on Biological Effects of Ionizing Radiation, Board on Radiation Effects Research, Commission on Life Sciences, National Research Council. Health effects of exposure to low levels of ionizing radiation. In: Beir V (ed). Washington, DC: National Academy Press, 1990.
23. Brent RL. The effects of embryonic and fetal exposure to ionizing radiation: counseling the patient and worker about these risks. In: Mossman KL, Mill WA (eds). *The Biological Basis of Radiation Protection Practice*. Baltimore (MD): Williams & Wilkins, 1992: 3.
24. Brady JV, Reiter RJ. Neurobehavioural effects. In: *Health Effects of Low-Frequency Electric and Magnetic Fields*. Prepared by an Oak Ridge Associated Universities Panel for the Committee on Intergenerational Radiation Research and Policy Coordination (ORAU 92/F8, Chapter 7), Oak Ridge, TN, Oak Ridge Associated Universities, p. vii-1-vii-56.
25. A report of the committee to review the use of ionizing radiation for the treatment of benign diseases, Assembly of Life Sciences, National Research Council, National Academy of Sciences. In: Hilberg AW, telles NC, eds. *A Review of the Use of Ionizing Radiation for the Treatment of Benign Diseases*. Rockville (MD): US Department of Health Education and Welfare, 1977.
26. Chotas HG, Dobbins JT, Ravin CE. Principles of digital radiography with large-area, electronically readable detectors: a review of the basics. *Radiology* 1999; 210: 595–599.
27. Nikolaos K, Dimitriou M, Nikolos T, Alexandros R. Exposure to ionizing radiation and pregnancy. *Hellenic J Obstet Gynecol* 2015; 20(2): 49–56.
28. Russell JR, Stabin MG, Sparks RB, Watson EE. Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals. *Health Phys* 1997; 73: 756–769.
29. Damalikis J, Theocharopoulos N, Perisinaikis K, *et al*. Conceptus radiation dose and risk from cardiac catheter ablation procedures. *Circulation* 2003; 104: 893–897.
30. Otto CM. Principles of echocardiographic image acquisition and Doppler analysis. In: Otto CM. *Textbook of Clinical Echocardiography* (5th edn). Philadelphia, USA: Saunders/Elsevier, 2013, ch 1.
31. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). *J Am Soc Echocardiogr* 2003; 16(10): 1091–1110.
32. Hung J, Lang R, Flachskampf F, Sheran SK, McCulloch ML, Adams DB, *et al*. 3D echocardiography: A review of current status and future directions. ASE Position Paper. *J Am Soc Echocardiogr* 2007; 20: 213–233.
33. Ho CY, Solomon SD. A clinician’s guide to tissue Doppler imaging. *Circulation* 2006; 113: e396–e398.
34. Goresan J, Tanaka H. Echocardiographic assessment of myocardial strain. *J Am Coll Cardiol* 2011; 58: 1401–1413.
35. Copel JA, Piliu G, Green J, Hobbins J, Kleinman CS. Fetal echocardiographic screening for congenital heart disease: the importance of the four-chamber view. *Am J Obstet Gynecol* 1987; 157: 648–655.
36. US Department of Health and Human Services/Food and Drug Administration/Centre for Devices and Radiological Health/ Radiological Devices Branch/Division of Reproductive, Abdominal and Radiological Devices/Office of Device Evaluation/Division of Solid and Fluid Mechanics/Office of Science and Engineering Laboratories. Guidance for Industry and FDA Staff – Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers. US Food and Drug Administration; September 9, 2008.
37. Abramowics J, Barnett SB, Duck FA, Edmonds PD, Hynynen KH, Ziskin MC. Fetal thermal effects of diagnostic ultrasound. *J Ultrasound Med* 2008; 27: 541–559.
38. Dorbala S, Brozena S, Zeb S, Galatro K, Homel P, Ren JF, *et al*. Risk stratification of women with peripartum cardiomyopathy at initial presentation: adobutamine stress echocardiographic study. *J Am Soc Echocardiogr* 2005; 18: 45–48.
39. Goldman LW. Principles of CT and CT Technology. *J Nucl Med Technol* 2007; 35(3): 115–128.
40. Brenner DJ, Hall EJ. Computed tomography – An increasing source of radiation exposure. *N Eng J Med* 2007; 357: 2277–2284.
41. Lee CH, Goo JM, Ye HJ, Ye SJ, Park CM, Chun EJ, *et al*. Radiation dose modulation techniques in the multidetector CT era: from basises to practice. *Radiographics* 2008; 28(5): 1451–1459.
42. Hunsaker AR, Lu MT, Goldhaber SZ, Rybicki FJ. Advances in cardiovascular imaging: Imaging in acute pulmonary embolism with special clinical scenarios. *Circ Cardiovasc Imaging* 2010; 3: 491–500.
43. Stein PD, Athanasoulis C, Alavi A, Greenspan RH, Hales CA, Saltzman HA, *et al*. Complications and validity of pulmonary angiography in acute pulmonary embolism. *Circulation* 1992; 85: 462–468.
44. MacKenzie JD, Nazario-Larrieu J, Cai T, Ledbetter MS, Duran-Mendicutti MA, Judy PF, *et al*. Reduced-dose CT: effect on reader evaluation in detection of pulmonary embolism. *Am J Roentgenol* 2007; 189: 1371–1379.
45. Quroz R, Kucher N, Zou KH, Kipfmuller F, Costello P, Goldhaber SZ, *et al*. Clinical validity of a negative computed tomography scan in patients with suspected pulmonary embolism: a systematic review. *J Am Med Assoc* 2005; 293: 2012–2017.
46. Chan WS, Ray JG, Murray S, Coady GE, Coates, G, Ginsberg, JS. Suspected pulmonary embolism in pregnancy: Clinical presentation, results of lung scanning, and subsequent maternal and pediatric outcomes. *Arch Intern Med* 2002; 162: 1170–1175.
47. Winer-Muram HT, Boone JM, Brown HL, Jennings SG, Mabie WC, Lombardo GT. Pulmonary embolism in pregnant patients: fetal radiation dose with helical CT. *Radiology* 2002; 224: 487–492.
48. Damalikis J, Perisinaikis K, Vrahoriit G, Kontakis G, Varveris H, Courtsoyannis N. Embryo/fetus radiation dose and risk from dual X-ray absorptiometry examinations. *Osteopros Int* 2002; 13: 716–722.
49. Pennell DJ. Cardiovascular magnetic resonance. *Circulation* 2010; 121: 692–705.
50. Karamitsos TD, Francis JM, Myerson SG, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol 2009; 54(15): 1407–1424.
51. Aim DL, Narula J, Sengupta PP. Cardiovascular imaging and diagnostic procedures in pregnancy. Cardiol Clin 2012; 30(3): 331–341.
52. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imag 1999; 10: 477–484.
53. Mevissen M, Buntenkotter S, Loscher W. Effects of static and time-varying (50 Hz) magnetic fields on reproduction and fetal development in rats. Teratology 1994; 50: 229–237.
54. Beers GJ. Biological effects of weak electromagnetic fields from 0 Hz to 200 Hz: a survey of the literature with special emphasis on possible magnetic resonance effects. Mag Res Imag 1989; 7: 309–331.
55. Schwartz JL, Crooks LE. NMR imaging produces no observable mutations or cytotoxicity in mammalian cells. Am J Roentgenol 1982; 139: 583–585.
56. Wolff S, Crooks LE, Brown P, Howard R, Painter R. Test for DNA and chromosomal damage induced by nuclear magnetic resonance imaging. Radiology 1980; 136: 707–710.
57. Reeves MJ, Brandreth M, Whitby EH, Hart AR, Paley MN, Griffiths PD, et al. Neonatal cochlear function: measurement after exposure to acoustic noise during in utero MR imaging. Radiology 2010; 257: 802–809.
58. American College of Radiology. ACR-SPR practice parameter for the safe and optimal performance of fetal magnetic resonance imaging (MRI). Revised 2015 (Resolution 11). Available at: http://www.acr.org/~/media/ACR/Files/PracticeParameters/MRI/ACR-SPR-MRI-2015.pdf
59. Berman DS, Hachamovitch R, Shaw LJ, Friedman JD, Hayes SW, et al. ACR guidance document for safe MR practices: 2007. J Magn Reson Imag 2013; 37: 501–530.